Abstract
p53 is an important transcriptional regulator that is frequently mutated in cancer. Gene-profiling experiments of breast cancer cells infected with wt p53 revealed both MASPIN and desmocollin 3 (DSC3) to be p53-target genes, even though both genes are silenced in association with aberrant cytosine methylation of their promoters. Despite the transcriptional repression of these genes by aberrant DNA methylation, restoration of p53 resulted in the partial reactivation of both genes. This reactivation is a result of wt p53 binding to its consensus DNA-binding sites within the MASPIN and DSC3 promoters, stimulating histone acetylation, and enhancing chromatin accessibility of their promoters. Interestingly, wt p53 alone did not affect the methylation status of either promoter, suggesting that p53 itself can partially overcome the repressive barrier of DNA methylation. Pharmacologic inhibition of DNA methylation with 5-aza-2′-deoxycytidine in combination with restoration of wt p53 status resulted in a synergistic reactivation of these genes to near-normal levels. These results suggest that cancer treatments that target both genetic and epigenetic facets of gene regulation may be a useful strategy towards the therapeutic transcriptional reprogramming of cancer cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Antequera F, Boyes J and Bird A . (1990). Cell, 62, 503–514.
Barlev NA, Liu L, Chehab NH, Mansfield K, Harris KG, Halazonetis TD and Berger SL . (2001). Mol. Cell, 8, 1243–1254.
Bird AP and Wolffe AP . (1999). Cell, 99, 451–454.
Domann FE, Rice JC, Hendrix MJ and Futscher BW . (2000). Int. J. Cancer, 85, 805–810.
el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B . (1993). Cell, 75, 817–825.
Espinosa JM and Emerson BM . (2001). Mol. Cell, 8, 57–69.
Futscher BW, Oshiro MM, Wozniak RJ, Holtan N, Hanigan CL, Duan H and Domann FE . (2002). Nat. Genet., 31, 175–179.
Gu W, Shi XL and Roeder RG . (1997). Nature, 387, 819–823.
He TC, Zhou S, da Costa LT, Yu J, Kinzler KW and Vogelstein B . (1998). Proc. Natl. Acad. Sci. USA, 95, 2509–2514.
Hollstein M, Hergenhahn M, Yang Q, Bartsch H, Wang ZQ and Hainaut P . (1999). Mutat. Res., 431, 199–209.
Hollstein M, Sidransky D, Vogelstein B and Harris CC . (1991). Science, 253, 49–53.
Jones PA and Baylin SB . (2002). Nat. Rev. Genet., 3, 415–428.
Jones PA and Taylor SM . (1980). Cell, 20, 85–93.
Kannan K, Amariglio N, Rechavi G, Jakob-Hirsch J, Kela I, Kaminski N, Getz G, Domany E and Givol D . (2001). Oncogene, 20, 2225–2234.
Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C and Vogelstein B . (1991). Science, 252, 1708–1711.
Khan J, Simon R, Bittner M, Chen Y, Leighton SB, Pohida T, Smith PD, Jiang Y, Gooden GC, Trent JM and Meltzer PS . (1998). Cancer Res., 58, 5009–5013.
Klus GT, Rokaeus N, Bittner ML, Chen Y, Korz DM, Sukumar S, Schick A and Szallasi Z . (2001). Int. J. Oncol., 19, 169–174.
Lee D, Kim JW, Seo T, Hwang SG, Choi EJ and Choe J . (2002). J. Biol. Chem., 277, 22330–22337.
Levine AJ . (1997). Cell, 88, 323–331.
Litt MD, Simpson M, Recillas-Targa F, Prioleau MN and Felsenfeld G . (2001). EMBO J., 20, 2224–2235.
Maass N, Biallek M, Rosel F, Schem C, Ohike N, Zhang M, Jonat W and Nagasaki K . (2002). Biochem. Biophys. Res. Commun., 297, 125–128.
Maxwell SA and Davis GE . (2000). Proc. Natl. Acad. Sci. USA, 97, 13009–13014.
Meltzer P, Leibovitz A, Dalton W, Villar H, Kute T, Davis J, Nagle R and Trent J . (1991). Br. J. Cancer, 63, 727–735.
Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN and Bird A . (1998). Nature, 393, 386–389.
Ng HH, Zhang Y, Hendrich B, Johnson CA, Turner BM, Erdjument-Bromage H, Tempst P, Reinberg D and Bird A . (1999). Nat. Genet., 23, 58–61.
Polyak K, Xia Y, Zweier JL, Kinzler KW and Vogelstein B . (1997). Nature, 389, 300–305.
Rice JC and Futscher BW . (2000). Nucleic Acids Res., 28, 3233–3239.
Schena M, Shalon D, Davis RW and Brown PO . (1995). Science, 270, 467–470.
Seftor RE, Seftor EA, Sheng S, Pemberton PA, Sager R and Hendrix MJ . (1998). Cancer Res., 58, 5681–5685.
Soussi T, Dehouche K and Beroud C . (2000). Hum. Mutat., 15, 105–113.
Streuli CH . (2002). Breast Cancer Res., 4, 137–140.
Taylor SM and Jones PA . (1979). Cell, 17, 771–779.
Thompson F, Emerson J, Dalton W, Yang JM, McGee D, Villar H, Knox S, Massey K, Weinstein R, Bhattacharyya A et al. (1993). Genes Chromosom. Cancer, 7, 185–193.
Trent J, Yang JM, Emerson J, Dalton W, McGee D, Massey K, Thompson F and Villar H . (1993). Genes Chromosom. Cancer, 7, 194–203.
Tselepis C, Chidgey M, North A and Garrod D . (1998). Proc. Natl. Acad. Sci. USA, 95, 8064–8069.
Vogelstein B, Lane D and Levine AJ . (2000). Nature, 408, 307–310.
Wade PA, Gegonne A, Jones PL, Ballestar E, Aubry F and Wolffe AP . (1999). Nat. Genet., 23, 62–66.
Watts GS, Pieper RO, Costello JF, Peng YM, Dalton WS and Futscher BW . (1997). Mol. Cell. Biol., 17, 5612–5619.
Yu J, Zhang L, Hwang PM, Rago C, Kinzler KW and Vogelstein B . (1999). Proc. Natl. Acad. Sci. USA, 96, 14517–14522.
Zhang M, Shi Y, Magit D, Furth PA and Sager R . (2000a). Oncogene, 19, 6053–6058.
Zhang M, Volpert O, Shi YH and Bouck N . (2000b). Nat. Med., 6, 196–199.
Zhao R, Gish K, Murphy M, Yin Y, Notterman D, Hoffman WH, Tom E, Mack DH and Levine AJ . (2000). Genes Dev., 14, 981–993.
Zou Z, Anisowicz A, Hendrix MJ, Thor A, Neveu M, Sheng S, Rafidi K, Seftor E and Sager R . (1994). Science, 263, 526–529.
Zou Z, Gao C, Nagaich AK, Connell T, Saito S, Moul JW, Seth P, Appella E and Srivastava S . (2000). J. Biol. Chem., 275, 6051–6054.
Acknowledgements
We thank Bert Vogelstein for the control and wt p53 adenoviruses. We thank S Vaught, A Palazzo, M Fitzgerald, and the Arizona Cancer Microarray Core for technical assistance. NIH grants to BWF and to FED, as well as to the Arizona Cancer Center and the Gene Therapy Center at the University of Iowa supported this work. MO was supported by a Cancer Biology Training grant from the NIH, and RW received support from a Toxicology Training grant from the NIEHS.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Oshiro, M., Watts, G., Wozniak, R. et al. Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression. Oncogene 22, 3624–3634 (2003). https://doi.org/10.1038/sj.onc.1206545
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206545
Keywords
This article is cited by
-
Estradiol-mediated inhibition of DNMT1 decreases p53 expression to induce M2-macrophage polarization in lung cancer progression
Oncogenesis (2022)
-
Expression and associated epigenetic mechanisms of the Ca2+-signaling genes in breast cancer subtypes and epithelial-to-mesenchymal transition
Journal of Cell Communication and Signaling (2022)
-
Expression and localization of maspin in cervical cancer and its role in tumor progression and lymphangiogenesis
Archives of Gynecology and Obstetrics (2014)
-
Role of maspin in cancer
Clinical and Translational Medicine (2013)
-
Characterization of synergistic anti-cancer effects of docosahexaenoic acid and curcumin on DMBA-induced mammary tumorigenesis in mice
BMC Cancer (2013)